TATA HEALTH (01255) announced that on September 12, 2025, the company received a letter from the Hong Kong Stock Exchange. The letter sets out additional guidance for the resumption of trading of the company's shares on the Hong Kong Stock Exchange, specifically requiring: conducting an independent internal control review and demonstrating that the company has established sufficient internal controls and procedures to comply with its obligations under the listing rules.